ElectroCore ECOR shares are trading higher on Thursday after the company announced an agreement with UpScript to be the exclusive online telehealth provider for gammaCore Sapphire.
ElectroCore is a commercial-stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology.
The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients and the prevention of migraine in adult patients.
ElectroCore shares were trading up 1.92% at $1.70 at the time of publication. The stock has a 52-week high of $3.30 and a 52-week low of 32 cents.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
